Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - vincristine sulfate - solution for injection - 1mg, 5mg (douglas) - active: vincristine sulfate

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - vincristine sulfate 1mg - solution for injection - 1 mg - active: vincristine sulfate 1mg excipient: lactose monohydrate water for injection sodium chloride water for injection

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - vincristine sulfate 1 mg/ml - solution for injection - 1 mg/ml - active: vincristine sulfate 1 mg/ml excipient: acetic acid methyl hydroxybenzoate propyl hydroxybenzoate sodium acetate trihydrate water for injection

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

pharmacia limited company trading as pharmacia - vincristine sulfate 1 mg/ml - solution for injection - 1 mg/ml - active: vincristine sulfate 1 mg/ml excipient: mannitol water for injection

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - vincristine sulfate 2mg - solution for injection - 2 mg - active: vincristine sulfate 2mg excipient: lactose monohydrate water for injection sodium chloride water for injection

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - vincristine sulfate 5mg - solution for injection - 5 mg - active: vincristine sulfate 5mg excipient: lactose monohydrate water for injection sodium chloride water for injection

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

hospira uk ltd - vincristine sulfate - solution for injection - 5 mg/5ml

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

pharma regulatory solutions ltd - voriconazole - pdr for soln for infusion - 200 milligram - triazole derivatives - antimycotics for systemic use, triazole derivatives - voriconazole is a broad-spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows: treatment of invasive aspergillosis. treatment of candidaemia in non-neutropenic patients. treatment of fluconazole-resistant serious invasive candida infections (including c. krusei). treatment of serious fungal infections caused by scedosporium spp. and fusarium spp. voriconazole should be administered primarily to patients with progressive, possibly life-threatening infections. prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.

Umoja wa Ulaya - Kiingereza - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol - asthma - drugs for obstructive airway diseases, - budesonide/formoterol teva pharma b.v. is indicated in adults 18 years of age and older only.asthmabudesonide/formoterol teva pharma b.v. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists. 

Marekani - Kiingereza - NLM (National Library of Medicine)

talon therapeutics, inc. - vincristine sulfate (unii: t5iro3534a) (vincristine - unii:5j49q6b70f) - vincristine sulfate 5 mg in 5 ml - marqibo® is indicated for the treatment of adult patients with philadelphia chromosome-negative (ph-) acute lymphoblastic leukemia (all) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. this indication is based on overall response rate. clinical benefit such as improvement in overall survival has not been verified. marqibo is contraindicated in patients with demyelinating conditions including charcot-marie-tooth syndrome. marqibo is contraindicated in patients with hypersensitivity to vincristine sulfate or any of the other components of marqibo (vincristine sulfate liposome injection). marqibo is contraindicated for intrathecal administration. pregnancy category d [see warnings and precautions (5.9) ] based on its mechanism of action and findings from animal studies, marqibo can cause fetal harm when administered to pregnant women. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be